Neuroendocrine differentiation has been associated with prostate cancer (CaP). Brn-3a (short isoform) and Brn-3c, transcriptional controllers of neuronal differentiation, were readily detectable in human CaP both in vitro and in vivo. Brn-3a expression, but not Brn-3c, was significantly upregulated in 450% of tumours. Furthermore, overexpression of this transcription factor in vitro (i) potentiated CaP cell growth and (ii) regulated the expression of a neuronal gene, the Nav1.7 sodium channel, concomitantly upregulated in human CaP, in an isoform-specific manner. It is concluded that targeting Brn-3a could be a useful strategy for controlling the expression of multiple genes that promote CaP.
Introduction
Alteration of expression and/or functioning of transcription factors that regulate cellular differentiation is a frequent cause of neoplastic transformation and tumour progression. 1, 2 Consistent with this, a lack of differentiation (anaplasia) is a characteristic feature of cancer. 3 Brn-3 transcription factors (Brn-3a/3b/3c), a three-member family of POU (Pit, Oct, Unc) class IV homeobox proteins, (i) regulate the balance between cell proliferation and differentiation, and (ii) protect cells from apoptosis, in the nervous and neuroendocrine (NE) systems. 4, 5 By activating and repressing a wide variety of target gene promoters, either directly or through interactions with cofactors, [6] [7] [8] they strongly influence cell fate specification in the developing embryo 9 and help to maintain mature neuronal phenotypes in the adult. 4, 10 Expression of these transcription factors has also been found to be altered in a number of different cancers in vitro and in vivo. Thus, Brn-3a levels are significantly elevated (mRNA, B300-fold; protein, B6-fold) in cervical cancers 11 and are also high in aggressive NE tumours including small-cell lung carcinomas, 12 Ewing's sarcoma and neuroepitheliomas; 13 Brn-3b is expressed at high levels in neuroblastoma 14, 15 and teratocarcinoma cells 15 and its expression is upregulated in a subset of malignant breast cancers; 16 Brn-3c expression is reduced in small-cell (Merkel cell) carcinomas of the skin with poor prognosis. 17, 18 Brn-3a, Brn-3b and Brn-3c genes share a common structure, composed of two exons separated by a short intronic sequence. Use of an alternative promoter in this intron gives rise to second, shorter isoforms of Brn-3a and Brn-3b but not Brn-3c. [19] [20] [21] The longer 43 kDa isoforms of Brn-3a and Brn-3b (Brn-3a [l] and Brn-3b [l] ) contain an additional domain at the amino terminus absent in the shorter 33 kDa Brn-3a [s] and Brn-3b[s], which is required for the cell-specific regulation of target genes including a-internexin, BRCA1 and Bcl-2. [22] [23] [24] Thus, long and short isoforms can be functionally distinct.
Significant changes in neuronal/NE differentiation of prostatic epithelial cells is associated with prostate cancer (CaP) progression. 25, 26 In particular, pore-forming a-subunits (but not auxillary b-subunits) of voltage-gated Na þ channels (VGSCs), which are classically expressed at high levels in neuronal/excitable tissues, are overexpressed in CaP in vitro 27, 28 and in vivo. 29, 30 Importantly, expressed neuronal/NE markers are likely to play a direct role in disease progression. Thus, VGSC activity potentiates several cellular processes integral to metastasis in vitro.
27,31-33 Brn-3a is a potential VGSC transcription factor given that mRNA levels of several VGSC a-subunit (VGSCa) genes, including SCN9A/ Nav1.7, which is specifically upregulated in CaP, 29 are significantly altered in the sensory neurons of Brn-3a knockout mice. 34 Several other established Brn-3 target genes, particularly those with roles in apoptosis such as Bcl-2, Bcl-x, Bax and Hsp27, also exhibit altered expression in CaP. [35] [36] [37] In summary, (i) Brn-3 transcription factors play an important role in normal cellular (neuronal/NE) differentiation; (ii) their expression is altered in other tumours of reproductive (and NE) origin; and (iii) known Brn-3 target genes exhibit altered expression in CaP. Accordingly, in the present study, we investigated the expression of Brn-3 homeobox members in human CaP in vitro and in vivo.
Materials and methods
Cell culture, RNA extraction and cDNA synthesis Three human CaP cell lines (LNCaP, PC-3 and PC-3M) and a 'normal' human prostatic epithelial cell line immortalized with SV40 (PNT2-C2) were cultured as previously described. 27, 28, 38 RNA was extracted using Trizol (Invitrogen), according to the manufacturer's instructions. 1 mg of total RNA was used for singlestranded cDNA synthesis using Superscript II reversetranscriptase (Invitrogen) primed with 250 ng random hexamer mix. Reactions were performed in a final volume of 20 ml made up to 100 ml with H 2 O once the reverse-transcription process was completed.
Fixed end point RT-PCR and cloning
Specific PCRs for Brn-3a, Brn-3b and Brn-3c were performed on the cell lines, and on cDNA generated from T-lymphocyte Jurkat and TC32 neuroblastoma cells previously shown to express Brn-3a/3b/3c, 39 utilizing the primer pairs listed in Table 1 . Additionally, Brn-3a[l]-specific PCRs were also carried out to determine which isoforms of this transcription factor were expressed (Table 1) . Brn-3a and Brn-3b PCRs did not span introns, so PCR assays were also performed on cDNA reactions to which no reverse transcriptase was added to control for possible genomic contamination. Reactions were performed on 5 ml of the synthesized cDNA, as described previously. 28 In each PCR run, a blank reaction without added cDNA was also included in order to control for cross-contamination from other sources. All products were analysed by gel electrophoresis on 0.8% agarose gels and those derived from PC-3 cells were cloned as before 28 and sequenced.
Western blotting
Protein was extracted from cells using 1 Â RIPA-PI solution, containing protease inhibitor cocktail (Roche), 0.75 M. NaCl, 5% NP40 Igepal, 2.5% deoxycholate, 0.5% SDS, 0.25 M Tris-HCl (pH 8.0) and concentrations were determined using the BCA assay (Pierce). An equivalent amount of each of the extracts was run on 12.5% SDS-PAGE gels and electroblotted onto nitrocellulose membrane (Schleicher and Schuell) overnight. Blots were blocked in 5% (w/v) solution of non-fat dried milk in PBS (0.1% Tween-20), probed with either a 1:1000 dilution of monoclonal mouse anti-Brn-3a (Chemicon) or polyclonal goat anti-b-actin antibody (Santa Cruz), incubated with a 1:2000 dilution of an appropriate HRP-tagged secondary antibody and developed using the ECL chemiluminescence assay (Amersham Life Sciences). 29 RNA was extracted from biopsy tissues using StrataPrep Total RNA Miniprep kits (Stratagene) with a modified protocol, as described previously. 29 For immunohistochemistry, sections of human prostate from 30 different patients (from radical prostatectomies), fixed in 10% formalin and embedded in paraffin, provided by the Royal Liverpool University Hospital, were used. All tissues were obtained with local ethics approval and subsequent to the signing of informed consent forms.
Real-time PCR
Real-time PCR was performed using SYBR I Green technology on the DNA Engine Opticon system (MJ Research) as described before. 29 Targets for which relative expression levels in the samples were determined were Brn-3a, Brn-3b, Brn-3c and IL-6 (known to be expressed at greatly increased levels in CaP tissues 40 ). The primer pairs used are shown in Table 1 . Triplicate reactions for each amplicon were carried out simultaneously for each sample cDNA. PCRs worked with similar efficiencies, as determined by reactions performed on serial dilutions of cDNA derived from LNCaP cells (data not shown). Target expression was normalized relative to the levels of two different types of samplematched normalizing gene: (i) Input normalizer (b2 microglobulin, B2M; b-actin), controlling for variables including sample-to-sample differences in RNA input, RNA quality and reverse-transcription efficiency that might contribute to apparent inter-sample expression differences; (ii) Epithelial cell type normalizer (cytokeratin-8), controlling for specific differences or changes in relative epithelial cell type proportions between different samples. The sequences and annealing temperatures of the normalizing gene primer pairs used are shown in Table 1 .
Immunohistochemical staining
Sections were de-waxed by treatment with xylene for 2 Â 10 min and subsequently re-hydrated with 2 Â 10 min steps in 100 and 95% ethanol and distilled water. Antigen retrieval was achieved by boiling the sections in freshly made 0.01 M citrate buffer (pH 6.6) in a microwave oven for 5 min. Sections were blocked with 3% milk in PBST (PBS supplemented with 0.4% Triton-X) for 1 h and then incubated with a 1:75 dilution mouse anti-Brn-3a (Chemicon) antibody in 3% milk/PBST at room temperature for 18 h. Negative controls in which the primary antibody was omitted were also carried out. Sections were washed three times for 5 min with PBST and visualization was achieved by incubating for 1 h with biotinylated rabbit anti-mouse secondary antibody (DAKO) and then for 45 min with avidin-biotin complex (DAKO). Slides were subjected to a final diaminobenzidine application for 10 min to reveal the brown stain, dehydrated in 95 and 100% ethanol solutions, cleared in xylene and mounted with DPX. The pathological character of each section was determined by a single pathologist (CSF).
A scoring system was devised to quantify the 'overall staining intensity' (OSI) for each section: OSI-1, detectable but very low expression, predominantly localized to the nuclei of both basal and luminal epithelial cells; OSI-2, predominantly epithelial cell restricted, nuclearspecific; OSI-3, less epithelial cell restricted, nuclear and cytoplasmic staining; and OSI-4, stronger, more ubiquitous expression (both epithelial and non-epithelial), localized in both the nucleus and cytoplasm of epithelial/tumour cells. This analysis was performed by a single observer (JKJD) for consistency.
Stable transfection of PC-3 cells with Brn-3a
PC-3 cells were plated in three 10 cm dishes at a density of 2 Â 10 5 cells/dish in normal growth medium (without antibiotics). Transfections were performed in serum-free growth medium 48 h after plating using Lipofectamine reagent, according to the manufacturers' instructions (Invitrogen). To each dish was added 20 ml of Lipofectamine reagent and 3 mg of DNA, composed of 0.5 mg of the G418-resistance containing Neo expression vector and 2.5 mg of (i) pLTRpoly or (ii) Brn-3a[l] pLTRpoly or (iii) Brn-3a[s] pLTRpoly. These Brn-3a expression vectors were produced by amplifying full-length cDNA from ND7 RNA (primers contained EcoRI and BamHI restriction sites for subsequent cloning, first into pBluescript and then into the pLTRpoly vector, prior to full sequencing; primer pairs are listed in Table 2 ). After 5 h, cells were re-fed with normal growth medium (10% FBS) containing 1% penicillin-streptomycin. After 2 days, cells were split 1:3 and selected with the addition of 300 mg ml À1 geneticin (G418, GIBCO) that was subsequently refreshed every 3 days. At days 10-15, transfectant colonies were picked manually with a pipette and transferred to 24-well plates. Clones were grown in 300 mg ml À1 geneticin to produce cell stocks. Resultant clones were then re-plated in 10 cm plates at a density of 3.1 Â 10 5 cells/dish and their protein or RNA harvested after 2 days in order to determine the success of the transfection. Table 2 Primer pairs used to generate Brn-3a expression vectors
Target
Primer sequences Direction
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Growth curves
Four independent clones of each of the three PC-3 transfectants were grown to B80% confluency and harvested by trypsin/versene. Cells were plated at a density of 1 Â 10 4 cells/well in 1 ml of normal growth medium supplemented with 10% FBS in 24-well plates. Medium was replaced every 3 days for the duration of the experiment (20 days). Every 2 days, triplicate wells were harvested and cells counted using a haemocytometer. Results were expressed as means7s.d's.
Determination of Nav1.7 mRNA levels in PC-3 transfectants
Real-time PCR assays were performed, as above, using Nav1.7-specific primers (Table 1 ) on three independent clones of each of the PC-3 stable transfectant types overexpressing Brn-3a, with subsequent quantitative analyses carried out using the input normalizers B2M and b-actin (as above). Results were expressed as means7s.d's for each transfectant type. Nav1.7 real-time PCRs were also performed on PC-3 cells transiently overexpressing the Brn-3a isoforms. Transient transfections were performed in duplicate, as for stable transfections, except that RNA was extracted 24 h after lipofectamine/DNA application (before G418 selection), and Nav1.7 levels were normalized to B2M.
Data analysis
Further to the details given above for specific procedures, t-tests were performed on transfectant cell growth data. In vivo differences between non-CaP and CaP were determined by testing normalized medians for statistical significance with the non-parametric Mann-Whitney U-test.
Results
Brn-3 transcription factor expression in prostatic epithelial cells in vitro RT-PCR assays detected Brn-3a and Brn-3c mRNA expression in the four prostatic epithelial cell lines studied and the T-lymphocyte Jurkat cell positive controls (Figure 1a) . In contrast, Brn-3b mRNA could not be amplified from any of these cells, although it was readily amplified in TC32 neuroblastoma cells used as a positive control. Brn-3a protein was also evident in all four cell lines using an anti-Brn-3a antibody, which recognizes both long (Brn-3a[l]) and short (Brn-3a[s]) isoforms (Figure 1b) . Blots showed Brn-3a[s] but not Brn3a[l] protein expression, indicating that Brn-3a[s] was the predominant isoform expressed in all prostatic epithelial cells in vitro. This was consistent with the data from isoform-specific RT-PCR assays: Brn-3a[l] amplicons were only generated from the cell lines after extensive amplification, despite the PCR efficiency being comparable to non-isoform specific Brn-3a assays (data not shown). Brn-3a[s]-specific RT-PCRs could not be performed as efficient assays were not possible (since 495% of the Brn-3a[s] mRNA sequence is also present in the Brn-3a[l] transcript and the remaining 5% is highly repetitive). In summary, Brn-3a, predominantly in its short isoform, and Brn-3c (but not Brn-3b) were readily detected in prostatic epithelial and CaP cell lines.
Brn-3a mRNA upregulation in CaP in vivo
Brn-3a and Brn-3c, but not Brn-3b mRNAs, were amplified from human prostate biopsies using real-time PCR (Figure 2a) . Most (n ¼ 15/17) biopsy samples expressed Brn-3a but only a subset of these (n ¼ 6/15) yielded amplicons from Brn-3a[l]-specific RT-PCR assays after extensive amplification. Thus, in vivo, Brn-3a was also predominantly expressed as Brn-3a[s]. Importantly, Brn-3a expression levels were significantly higher in CaP vs non-CaP samples (22.7-fold, B2M normalizer, Po0.05; Figure 2b ), and also evident even when corrected for increased epithelial cell numbers in CaP samples using the cytokeratin-8 normalizer. In contrast, Brn-3c mRNA levels were similar in these two patient groups (Figure 2c ). IL-6, known to be expressed at greatly increased levels in CaP tissues, 40 was used as a positive control and showed a 20-fold increase (Po0.05; B2M normalizer) in CaP vs non-CaP.
Brn-3a protein localization in vivo
In non-CaP tissues (n ¼ 10), Brn-3a expression was detectable but very low and predominantly localized to the nuclei of both basal and luminal epithelial cells (Figure 3a) . In CaP tissues, 14/20 samples showed stronger reactivity than non-CaP samples, with staining again mainly localized to epithelial cells (Figure 3b-d) . The remaining six CaP samples exhibited staining levels Brn-3 transcription factors in prostate cancer JKJ Diss et al comparable to non-CaP tissues that was restricted to epithelial cells (Figure 3e ). The overall expression of Brn3a was significantly higher in CaP than non-CaP tissues (OSI ¼ 2.270.2 vs 1.170.1; Po0.05).
In conclusion, the in vivo data show (i) that Brn-3a/b/c expression was qualitatively similar to in vitro, with only Brn-3a and Brn-3c expressed; (ii) that Brn-3a (but not Brn-3c) mRNA and protein levels were increased in CaP; and (iii) that Brn-3a expression was mainly restricted to epithelial/epithelial-derived (CaP) cells.
Functional effects of Brn-3a overexpression
In order to determine the possible functional significance of Brn-3a in CaP, both isoforms were overexpressed in the well-characterized PC-3 cell line (Figure 4a ) and two independent assessments were made, as follows:
( 1 (Figure 4b ). In contrast, Brn-3a[l] transfectant growth was somewhat variable but, on average, was not markedly different from pLTRpoly controls.
(2) Target gene (Nav1.7) regulation. mRNA levels of a possible target of Brn-3a, similarly upregulated in CaP in vivo (and of functional significance to CaP progression), the Nav1.7 VGSCa, were measured by real-time PCR. Average Nav1.7 levels in Brn-3a[s] transfectants were 2.6-fold greater than in pLTRpoly controls (Po0.05; Figure 5a ). In contrast, again, levels in Brn-3a[l] transfectants were not significantly altered (Figure 5a ). The upregulation of Nav1.7 expression was likely to be due, at least in part, to direct transcriptional regulation of the Nav1.7 promoter by Brn-3a[s] specifically, since this effect was also evident following transient overexpression in PC-3 cells; 24 h after transfection, Brn-3a[s] overexpression resulted in a significant 1372.6% increase in Nav1.7 mRNA levels (Po0.05; Figure 5b ).
Discussion
In this study, we investigated, for the first time, the expression of the three members of the Brn-3 POU homeobox neuronal transcription factor family in human prostate. Brn-3a was expressed predominantly in its short form (Brn-3a[s]) in vitro and in vivo, and showed significant increases at both mRNA and protein expression levels in CaP in vivo. Furthermore, overexpression of this transcription factor in vitro produced functional effects consistent with its upregulation in vivo (i) potentiating CaP cell growth, and (ii) upregulating the expression of a 'neuronal' gene, the Nav1.7 VGSC, known also to be expressed at high levels in human CaP in vitro 29 and in vivo. [27] [28] [29] [30] These effects were specific for the 'short' isoform of Brn-3a (Brn-3a[s] ). Expression of Brn-3b and Brn-3c, both previously associated with other cancers, [14] [15] [16] [17] [18] did not exhibit any marked change in CaP; in fact, Brn-3b was not detectable either in vitro or in vivo.
Expression of Brn-3a in 'normal' human prostate
We found that Brn-3a was expressed in prostatic epithelial cells in vitro, and predominantly in prostatic epithelial ducts in vivo. Immunohistochemistry on nonCaP samples showed that low Brn-3a expression was evident in both proliferative basal cells and highly differentiated secretory/luminal cells within the glandular prostate. It is noteworthy that non-CaP tissues used in this study were obtained from patients with BPH, a noncancerous condition considered here to represent the 'normal' age-matched control for CaP. Consequently, whether the observed epithelial Brn-3a expression was a result of BPH or is a phenomenon of the 'normal', undiseased prostate remains to be determined. Importantly, Brn-3a expression had a specifically nuclear Brn-3 transcription factors in prostate cancer JKJ Diss et al localization, suggesting that it is likely to be functionally active. Brn-3 expression has been detected but not specifically localized to epithelial cells in several other adult reproductive tissues, including ovary, uterus and testis. 22, 23 In the nervous system, where expression is high, Brn-3a has a major role in growth, differentiation and survival/protection from apoptosis, regulating the expression of key growth genes including Bcl-2, Bcl-x and Bax. It is possible that Brn-3a functions similarly in prostatic epithelial cells.
Upregulation of Brn-3a[s] in CaP and role in growth
Brn-3a mRNA and protein levels (specifically the short isoform) were significantly upregulated in 450% of tumours. Consistent with a direct role in tumorigenesis, overexpression of this transcription factor also potentiated in vitro CaP cell growth. Expression of high levels of Brn-3a have previously been found in cervical, NE cancers and Ewing's sarcoma. [11] [12] [13] However, Brn-3a expression has only been compared to levels in corresponding noncancer tissue in cervical cancer, and found Brn-3 transcription factors in prostate cancer JKJ Diss et al to be upregulated. 11 Similar to the present study, overexpression of Brn-3a was found to increase cervical cancer cell growth in vitro and tumour growth in vivo. 41, 42 Brn-3a was expressed in its short rather than long isoform in CaP. In contrast, Brn-3a[l] was predominant in cervical cancer (D Ndisang, personal communication), NE tumours 12 and Ewing's sarcoma (D Gascoyne, personal communication). Functional differences between alternative Brn-3 transcription factor isoforms have been noted before, but typically involve significant effects of the long isoform which are not reproduced by the shorter isoform. [22] [23] [24] For example, overexpression of Brn-3a[l] but not Brn-3a[s] was found to be oncogenic in primary rat embryonic fibroblasts, conferring upon them the capability for anchorage-independent cell growth. 19 Additonally, only Brn-3a[l], possessing both the POU homeodomain and an N-terminal activation domain, was found to regulate the promoters of BRCA1, a-internexin and Bcl-2 in neuroblastoma and breast cancer cells. [22] [23] [24] In the present study, we determined that overexpression of only Brn-3a[s] (and not Brn-3a[l]) had marked effects on growth. This isoform specificity would suggest that Brn-3a[s] might regulate important growth-related target genes in CaP cells, such as Bcl-2, Bcl-x, Bax, Hsp27. [35] [36] [37] Brn-3a regulation of Nav1.7
CaP progression is associated with significant changes in neuronal/NE differentiation of prostatic epithelial cells 25, 26 and 'neuronal' genes/markers, including SCN9A/Nav1.7, are both upregulated in CaP and have potential functional roles in metastasis. 29, [31] [32] [33] In this study, we observed Brn3a[s]-specific transcriptional regulation of SCN9A/Nav1.7 in PC-3 cells with both stable and transient overexpression of this transcription factor. This is the first example of gene regulation by the short isoform of a Brn-3 protein only.
To date, limited research has been directed towards identification of the promoter regions and transcription factors controlling VGSCa transcription. Basal promoters of only four of the 10 VGSCa genes have been characterized: the closely related Nav1.2 43 and Na X 44 genes on chromosome 2, and the major skeletal muscle VGSCas Nav1.4 45 and Nav1.5; 46, 47 and only one VGSCa transcription factor (the 'neuronrestrictive silencing factor', NRSF/REST) has been found. 48 Our previous findings showed that VGSC levels are increased in CaP and breast cancer in vitro and in vivo, 29, 49 and consistent with this NRSF/REST has recently been found to act as a tumour suppressor. 50 Brn-3a has a possible role in the transcriptional regulation of at least three VGSCas (Nav1.7, Nav1.8 and Nax) since their levels were decreased in the sensory neurons of Brn-3a knockout mice. 34 This supports a role for Brn3a in upregulating Nav1.7 expression, as demonstrated here. Brn-3a may therefore represent the second transcription factor that regulates VGSCa mRNA levels and an important determinant of Nav1.7 expression in CaP in vivo.
The Nav1.7 VGSC has been shown to potentiate cellular processes integral to CaP metastasis in vitro, especially invasion 27, [31] [32] [33] and VGSCs have been found to increase the invasiveness of lymphocytes and breast cancer cells. 49, 51 Brn-3 proteins have also recently been found to have a role in cellular invasion, with overexpression of Brn-3b significantly potentiating neuroblastoma cell invasion through Matrigel. 52 The mechanism(s) by which Brn-3b increases invasion is presently unknown but might include VGSC upregulation. Brn-3 transcription factors in prostate cancer JKJ Diss et al
Concluding remarks
The results presented here support the hypothesis that Brn-3 homeobox members (specifically Brn-3a, in its short isoform) play a significant role in CaP tumorigenesis (e.g. by altering cellular growth) and progression (e.g. by regulating the Nav1.7 VGSC and its involvement in metastasis). The possibility remains that Brn-3a also controls other genes involved in CaP and its progression such as Bcl-2, Bcl-x, Bax, Hsp27 and Nav1.7, established targets of Brn-3a. 28, 23, 53, 54 Ultimately, therefore, manipulating Brn-3a expression may prove to be an effective clinical strategy for limiting the activity of multiple genes in promoting CaP onset and progression.
